921201-92-5

Basic information

• Product Name: 1-Pyrrolidinepropanamide, N-(4-azidophenyl)-
• CAS NO: 921201-92-5
• Molecular Formula: C13H17N5O
• Molecular Weight: 259.311
• Mol File: 921201-92-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinepropanamide, N-(4-azidophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinepropanamide, N-(4-azidophenyl)-(921201-92-5)
• EPA Substance Registry System: 1-Pyrrolidinepropanamide, N-(4-azidophenyl)-(921201-92-5)

Safety Data

• Hazardous Substances Data: 921201-92-5(Hazardous Substances Data)

Usage

Chemical class

Pyrrolidines

Molecular weight

228.282 g/mol

Common uses

Organic synthesis, pharmaceutical research, development of new drugs and bioactive molecules

Unique chemical properties

Azido group

Applications

Modification of biomolecules and polymers, biomedical and materials science

Stability and flexibility

Pyrrolidine ring structure

Safety precautions

Handle with caution and appropriate safety measures in the laboratory due to the presence of the azido group.

Upstream product

• 100-01-6 4-nitro-aniline 
• 851651-95-1 N-(4-nitro-phenyl)-3-(pyrrolidin-1-yl)-propionamide 
• 393570-64-4 N-(4-amino-phenyl)-3-(pyrrolidin-1-yl)-propionamide 
• 19313-88-3 3-chloro-N-(4-nitrophenyl)propanamide 

Downstream Products

• 1070978-33-4 1-(3-(1-(4-(3-(pyrrolidin-1-yl)propanamido)phenyl)-1H-1,2,3-triazol-4-yl)phenyl)-3-(3-(1-(4-(acrylamido)phenyl)-1H-1,2,3-triazol-4-yl)phenyl)urea 
• 1070978-31-2 1,3-bis(3-(1-(4-(3-(pyrrolidin-1-yl)propanamido)phenyl)-1H-1,2,3-triazol-4-yl)phenyl)urea 
• 1400645-93-3 C₄₀H₄₂N₁₀O₂ 
• 1622093-58-6 N-(4-(4-((4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)-3-(pyrrolidin-1-yl)propanamide 
• 1262546-40-6 C₅₁H₅₇N₁₅O₃ 
• 1070978-42-5 1,3-bis(4-(1-(4-(3-(pyrrolidin-1-yl)propanamido)phenyl)-1H-1,2,3-triazol-4-yl)phenyl)urea 

Relevant articles and documents

Synthesis and characterization of 1H-phenanthro[9,10-d]imidazole derivatives as multifunctional agents for treatment of Alzheimer's disease

Background Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder that is characterized by dementia, cognitive impairment, and memory loss. Diverse factors are related to the development of AD, such as increased level of β-amyloid (Aβ), acetylcholine, metal ion deregulation, hyperphosphorylated tau protein, and oxidative stress. Methods The following methods were used: organic syntheses of 1H-phenanthro[9,10-d] imidazole derivatives, inhibition of self-mediated and metal-induced Aβ1-42 aggregation, inhibition studies for acetylcholinesterase and butyrylcholinesterase, anti-oxidation activity studies, CD, MTT assay, transmission electron microscopy, dot plot assay, gel electrophoresis, Western blot, and molecular docking studies. Results We synthesized and characterized a new type of 1H-phenanthro[9,10-d]imidazole derivatives as multifunctional agents for AD treatment. Our results showed that most of these derivatives exhibited strong Aβ aggregation inhibitory activity. Compound 9g had 74% Aβ1-42 aggregation inhibitory effect at 10 μM concentration with its IC50 value of 6.5 μM for self-induced Aβ1-42 aggregation. This compound also showed good inhibition of metal-mediated (Cu2 + and Fe2 +) and acetylcholinesterase-induced Aβ1-42 aggregation, as indicated by using thioflavin T assay, transmission electron microscopy, gel electrophoresis, and Western blot. Besides, compound 9g exhibited cholinesterase inhibitory activity, with its IC50 values of 0.86 μM and 0.51 μM for acetylcholinesterase and butyrylcholinesterase, respectively. In addition, compound 9g showed good anti-oxidation effect with oxygen radical absorbance capacity (ORAC) value of 2.29. Conclusions Compound 9g was found to be a potent multi-target-directed agent for Alzheimer's disease. General significance Compound 9g could become a lead compound for further development as a multi-target-directed agent for AD treatment.

Structure-based design of selective high-affinity telomeric quadruplex-binding ligands

A library of triazole-based telomeric quadruplex-selective ligands has been developed that mimic an established family of tri-substituted acridine-based ligands, using crystal structure data as a starting-point for computer-based design. Binding affinities, estimated by electrospray mass spectrometry, are in accord with the design concept.

THERAPEUTIC G-QUADRUPLEX LIGANDS

The invention provides compounds of formula (I): wherein Ar1 is a monocyclic aryl or heteroaryl; X and Y are each independe ntly a group of formula (II): Z is absent, a group of formula (II), optionally substituted C1-7 alkyl, optionally substituted C3-20 heterocyclyl, optionally substituted C5-20 aryl, halo, amino, hydroxy, ether, thio, thioet her, carboxy or cyano; L1 and L2 are each independently selected from NR 3, C2H2, CH2, -O-, -S- and a bond; Ar2 and Ar3 are independently optionally substituted C 5 or C6 aryl or heteroaryl; n is an integer from 1 to 5; R1 and R2 are independently hydrog en, C1-7 alkyl, C3-20 heterocyclyl, or C 5-20 aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; R3 is H or C 1-7 alkyl; and provided that at least one of Ar 1, Ar2 and Ar3 is oxazole, triazole or tetrazole. These compounds are thought to bind G -quadruplexes formed in human telomeres and are therefore useful in anti -cancer therapy. The invention also provides pharmaceutical compositions comprising the novel compounds, and methods for their manufacture.